检索结果 - Meletios Dimopoulos

  • Showing 1 - 8 results of 8
Refine Results
  1. 1

    Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone... 由 Meletios Dimopoulos, Michael Wang, Vladimir Maisnar, Jiri Minarik, William Bensinger, Maria-Victoria Mateos, Mihaela Obreja, Julie Blaedel, Philippe Moreau

    发表在 Journal of Hematology & Oncology (2018-04-01)
    获取全文
    文件


  2. 2

    Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma 由 Meletios Dimopoulos, Pieter Sonneveld, Salomon Manier, Annette Lam, Tito Roccia, Jordan M. Schecter, Patricia Cost, Lida Pacaud, Abbey Poirier, Gabriel Tremblay, Tommy Lan, Satish Valluri, Shaji Kumar

    发表在 BMC Cancer (2024-04-01)
    获取全文
    文件


  3. 3

    ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VERSUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA (IKEMA): FINAL OVERALL SURVIVAL ANALYSIS 由 Ecenur Guder Arslan, Kwee Yong, Thomas Martın, Meletios Dımopoulos, Joseph Mıkhael, Marcelo Capra, Thierry Facon, Roman Hájek, Ivan Špıčka, Ross Baker, Kihyun Kım, Gracia Martınez, Chang-Ki Mın, Philippe Moreau

    获取全文
    文件


  4. 4

    Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis 由 Marcelo Capra, Thomas Martin, Philippe Moreau, Ross Baker, Ludek Pour, Chang-Ki Min, Xavier Leleu, Mohamad Mohty, Marta Reinoso Segura, Mehmet Turgut, Richard LeBlanc, Marie-Laure Risse, Laure Malinge, Sandrine Schwab, Meletios Dimopoulos

    发表在 Haematologica (2021-10-01)
    获取全文
    文件


  5. 5

    Once‐weekly (70 mg/m2) vs twice‐weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., a... 由 Philippe Moreau, Keith A. Stewart, Meletios Dimopoulos, David Siegel, Thierry Facon, James Berenson, Noopur Raje, Jesus G. Berdeja, Robert Z. Orlowski, Hui Yang, Haijun Ma, Zandra Klippel, Anita Zahlten‐Kumeli, Khalid Mezzi, Karim Iskander, Maria‐Victoria Mateos

    发表在 Cancer Medicine (2020-05-01)
    获取全文
    文件


  6. 6

    Is Good Clinical Practice Becoming Poor Clinical Care? 由 Steven Le Gouill, Martin Dreyling, Maria Dolores Caballero, Marc Andre, Jeannette Doorduijn, Wojciech Jurczak, Mats Jerkeman, Paolo Ghia, Pier-Luigi Zinzani, Maria Gomez Da Silva, Meletios Dimopoulos, Marek Trneny, Richard Delarue, Jan Walewski, Christian Gisselbrecht, Armando López-Guillermo, Simon Rule

    发表在 HemaSphere (2017-12-01)
    获取全文
    文件


  7. 7

    From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives 由 Francesca Gay, Monika Engelhardt, Evangelos Terpos, Ralph Wäsch, Luisa Giaccone, Holger W. Auner, Jo Caers, Martin Gramatzki, Niels van de Donk, Stefania Oliva, Elena Zamagni, Laurent Garderet, Christian Straka, Roman Hajek, Heinz Ludwig, Herman Einsele, Meletios Dimopoulos, Mario Boccadoro, Nicolaus Kröger, Michele Cavo, Hartmut Goldschmidt, Benedetto Bruno, Pieter Sonneveld

    发表在 Haematologica (2018-02-01)
    获取全文
    文件


  8. 8

    2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde 由 Pellegrino Musto, Monika Engelhardt, Jo Caers, Niccolo’ Bolli, Martin Kaiser, Niels van de Donk, Evangelos Terpos, Annemiek Broijl, Carlos Fernández de Larrea, Francesca Gay, Hartmut Goldschmidt, Roman Hajek, Annette Juul Vangsted, Elena Zamagni, Sonja Zweegman, Michele Cavo, Meletios Dimopoulos, Hermann Einsele, Heinz Ludwig, Giovanni Barosi, Mario Boccadoro, Maria-Victoria Mateos, Pieter Sonneveld, Jesus San Miguel

    发表在 Haematologica (2021-07-01)
    获取全文
    文件


检索工具: